1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Recurrent Breast Adenocarcinoma: new trials by email Literature Review of Recurrent Breast Adenocarcinoma trials Research Report on Recurrent Breast Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
Breast Neoplasms (1)
Breast Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
2C4 antibody (1) · Biopsy (1) · CT-P6 (1) · Docetaxel (1) · Magnetic Resonance Spectroscopy (1) · Ogivri (1) · Ontruzant (1) · PF-05280014 (1) · Paclitaxel (1) · Taxes (1) · Trastuzumab (1) · atezolizumab (1) · pertuzumab (1) · trastuzumab biosimilar HLX02 (1)
National Cancer Institute (NCI) (1)
Canada (1) · United States (1)
Charles E Geyer (1)
U10CA180868 (1)